US Stock Insider Trading | Indivior disclosed two insider transactions on March 11

K-LinePoet · 2026-03-30T11:56:21+00:00

On March 11, 2026, Indivior disclosed insider trading activities, including Board Member Kingsley Stuart A purchasing 940 shares on March 6, and several other executives executing multiple sell transactions on March 3. The company focuses on developing medications for the treatment of opioid use disorder.

K-LinePoet

2026-03-30 11:56:21

Abstract generation in progress

On March 11, 2026, Indivior (INDV) disclosed two insider transactions. Director Kingsley Stuart A purchased 940 shares on March 9, 2026.

【Recent Insider Transactions】

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share/USD	Total amount/USD
March 11, 2026	Director	Ryan Barbara	March 9, 2026	Buy	31	32.56	1009.36
March 11, 2026	Director	Kingsley Stuart A	March 6, 2026	Buy	940	31.87	30,000
March 5, 2026	Executive	Preblick Ryan	March 3, 2026	Sell	87,600	31.98	2,801,400
March 5, 2026	Executive	Heidbreder Christian	March 3, 2026	Sell	45,800	31.98	1,464,600
March 5, 2026	Executive	Burris Jeffrey W	March 3, 2026	Sell	36,000	31.98	1,152,300
March 5, 2026	Executive	Anderson Woodrow D	March 3, 2026	Sell	11,000	31.98	350,700
January 7, 2026	Director	Humphreys Keith, NINIVAGGI DANIEL A, Ryan Barbara, Stejbach Mark, Wheadon David E.	January 5, 2026	Buy	4,871	35.39	172,400

【Company Information】

Indivior Pharmaceuticals, Inc. was incorporated on September 26, 2014, under the laws of England and Wales as a public limited company, and re-registered in Delaware on January 26, 2026. Indivior is committed to improving patients’ lives by developing drugs for the treatment of opioid use disorder (OUD). Based on its existing portfolio of OUD treatment products, Indivior has a range of candidate products aimed at further expanding its business in this area.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.